Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
REVB Price/Volume Stats
| Current price | $0.30 | 52-week high | $25.26 |
| Prev. close | $0.31 | 52-week low | $0.30 |
| Day low | $0.30 | Volume | 477,700 |
| Day high | $0.32 | Avg. volume | 937,327 |
| 50-day MA | $0.71 | Dividend yield | N/A |
| 200-day MA | $1.49 | Market Cap | 1.27M |
REVB Stock Price Chart Interactive Chart >
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
REVB Price Returns
| 1-mo | -60.16% |
| 3-mo | -64.47% |
| 6-mo | -87.50% |
| 1-year | -98.13% |
| 3-year | -100.00% |
| 5-year | N/A |
| YTD | -98.00% |
| 2023 | -92.47% |
| 2022 | -98.14% |
| 2021 | 1.49% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...